In a filing, Verve Therapeutics Inc revealed its Chief Executive Officer Kathiresan Sekar unloaded Company’s shares for reported $40761.0 on Apr 02 ’25. In the deal valued at $4.15 per share,9,822 shares were sold. As a result of this transaction, Kathiresan Sekar now holds 346,686 shares worth roughly $1.79 million.
Then, Nickerson Joan sold 2,777 shares, generating $11,525 in total proceeds. Upon selling the shares at $4.15, the Chief Administrative Officer now owns 17,420 shares.
Before that, Ashe Andrew D. sold 2,681 shares. Verve Therapeutics Inc shares valued at $11,126 were divested by the insider at a price of $4.15 per share. As a result of the transaction, Ashe Andrew D. now holds 348,828 shares, worth roughly $1.8 million.
Cantor Fitzgerald upgraded its Verve Therapeutics Inc [VERV] rating to an Overweight from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early April with a ‘”a Buy”‘ rating. Canaccord Genuity began covering VERV with “Buy” recommendation on April 13, 2023. Cantor Fitzgerald started covering the stock on February 01, 2023. It rated VERV as “a Neutral”.
Price Performance Review of VERV
On Monday, Verve Therapeutics Inc [NASDAQ:VERV] saw its stock fall -0.58% to $5.16. Over the last five days, the stock has lost -9.95%. Verve Therapeutics Inc shares have fallen nearly -8.51% since the year began. Nevertheless, the stocks have fallen -14.00% over the past one year. While a 52-week high of $9.31 was reached on 02/18/25, a 52-week low of $2.86 was recorded on 04/09/25. SMA at 50 days reached $5.32, while 200 days put it at $5.85.
Levels Of Support And Resistance For VERV Stock
The 24-hour chart illustrates a support level at 5.01, which if violated will result in even more drops to 4.87. On the upside, there is a resistance level at 5.28. A further resistance level may holdings at 5.41. The Relative Strength Index (RSI) on the 14-day chart is 50.67, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 51.36%. Stochastics %K at 64.45% indicates the stock is a holding.
The most recent change occurred on December 15, 2022 when Goldman began covering the stock and recommended ‘”a Sell”‘ rating along with a $13 price target.
